Baird Downgrades Amgen To Underperform On Overdone 'Exuberance' By: TalkMarkets January 31, 2020 at 07:57 AM EST Baird analyst Brian Skorney downgraded Amgen to Underperform from Neutral with a price target of $185, up from $173. Read More >> Related Stocks: Amgen